Jamie Chaft is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 569 publications with 32,541 citations (h-index 69); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
160 E 53rd St
9th Floor
New York, NY 100225243
Telephone
212-610-0590Registry record last updated 6 Apr 2015.
Clinical trials
- Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Sponsor: Memorial Sloan Kettering Cancer Center
- Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20256 payments$14,345openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year20251 payment
- AstraZeneca UK LimitedProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40.4%Kinase inhibitor40.4%Tagrisso72%Lorbrena9%Erlotinib Hcl6%Alecensa5%Xalkori4%Tepmetko3%Part D<11 patientsMetabolism & gastrointestinal
17.9%Proton pump inhibitor6.4%Pantoprazole Sodium62%Omeprazole39%Part D≥19 patientsCorticosteroid5.6%Prednisone100%Part D≥28 patients+ 2 more classes in this area
Sensory organs
12.2%Corticosteroid10.7%Dexamethasone100%Part D≥56 patientsFluoroquinolone Antibacterial1.5%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2013–2014 per NIH RePORTER. The latest:
- Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CT
Sloan-Kettering Inst Can Research
FY2014$486,303U01CA157442 - Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CT
Sloan-Kettering Inst Can Research
FY2013$583,127U01CA157442
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
New England Journal of Medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”